Aviva’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Aviva’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-35,074	Closed	-$2M	–	998
2019 Q4	$2M	Buy	+35,074	New	+$1.86M	0.01%	715

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Aviva's BSTC Position: Q1 2020 in Review

Aviva sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2020, closing a stake of 35,074 shares — an estimated $2M sold.

Aviva first reported a position in BSTC in Q4 2019 and held it in 1 quarter. The position peaked at $2M in Q4 2019. 113 funds tracked by Wall St. Rank hold BSTC as of Q1 2020.

Aviva reported no remaining BioSpecifics Technologies Corp. position as of Q1 2020 after selling out during the quarter.
Aviva sold 35,074 BioSpecifics Technologies Corp. shares in Q1 2020, an estimated $2M.
Aviva first reported a position in BioSpecifics Technologies Corp. in Q4 2019 and held it in 1 quarter.
Aviva's BioSpecifics Technologies Corp. position peaked at $2M in Q4 2019.
113 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2020.

Based on Aviva's 13F filing for Q1 2020, filed 14 May 2020.